Stock Details
LLY is Eli Lilly and Company's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 357.76$. Average daily volumn in 3 months 2.93M. Market cap 323.75B



Stock symbol : LLY. Exchange : NYSE. Currency : USD
Lastest price : 340.73$. Total volume : 2.29M. Market state POST
Click reload if you want to check the lastest price on market!!!

Eli Lilly and Company (LLY)
Last Price
340.73$
Change
1.05
Volume
2.29M

Previous Close339.68
Open338.56
Day Range337.82-342.87
Bid340.66 x 800
Ask343.43 x 800
Volume2.29M
Average Volume2.93M
Market Cap323.75B
Beta0.35
52 Week Range231.87-384.44
Trailing P/E51.86
Foward P/E29.02
Dividend (Yield %)1.33%
Ex-Dividend Date2023-02-14



Financial Details


According to Eli Lilly and Company's financial reports the company's revenue in 2022 were 28.54B an increase(0%) over the years 2021 revenue that were of 28.32B. In 2022 the company's total earnings were 6.24B while total earnings in 2021 were 5.58B( +20%).


Loading ...



Organization

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramz... a for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

eli-lilly-and-company-logo

Market Cap:
323.75B
Revenue:
28.54B


News about "Eli Lilly and Company"

eli-lilly-and-company-nyselly-is-largely-controlled-by-institutional-shareholders-who-own-85-of-the-company-image

Eli Lilly and Company (NYSE:LLY) is largely controlled by institutional shareholders who own 85% of the company

Source from : YAHOO!Finance - 1 days ago

Every investor in Eli Lilly and Company ( NYSE:LLY ) should be aware of the most powerful shareholder groups. With ...See details»


eli-lilly-and-company-nyselly-q4-2022-earnings-call-transcript-image

Eli Lilly and Company (NYSE:LLY) Q4 2022 Earnings Call Transcript

Source from : YAHOO!Finance - 3 days ago

Q4 2022 Earnings Call February 2, 2023 Operator: Ladies and gentlemen, thank you for standing by. And welcome to the Lilly Q4 2022 Earnings Conference Call. At this time, all participants are in a ...See details»


eli-lillys-post-earnings-decline-is-creating-a-buying-opportunity-for-long-term-investors-image

Eli Lilly's post-earnings decline is creating a buying opportunity for long-term investors

Source from : CNBC - 6 days ago

Club holding Eli Lilly's (LLY) post-earnings sell-off is creating a buying opportunity Thursday. Our long-term conviction is not shaken.See details»


eli-lillys-weak-fourth-quarter-sales-cloud-2023-profit-forecast-image

Eli Lilly's weak fourth-quarter sales cloud 2023 profit forecast

Source from : Reuters on MSN - 6 days ago

Eli Lilly and Co missed Wall Street estimates for quarterly revenue, hurt by slowing demand for its older diabetes drug and COVID-19 treatment, but forecast better-than-expected full-year profit.See details»


Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock

Source from : Nasdaq - 28 days ago

Eli Lilly (LLY) has been one of the most searched ... While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to ...See details»


Eli Lilly and Company News

Source from : TheStreet.com - 6 days ago

"We are committed to working with the FDA to ensure the fastest possible path to bring this potential medicine to patients in need," Eli Lilly said. Stock futures mixed with Fed talk, earnings in ...See details»


eli-lilly-earnings-show-9-sales-drop-on-covid-19-treatment-decline-image

Eli Lilly Earnings Show 9% Sales Drop on Covid-19 Treatment Decline

Source from : Wall Street Journal - 6 days ago

The pharmaceutical company said quarterly revenue fell 9% to $7.30 billion.See details»


Eli Lilly And Co. Reveals Rise In Q4 Bottom Line

Source from : Business Insider - 6 days ago

Eli Lilly And Co. (LLY) reported earnings for its fourth quarter that increased from last year The company's bottom line came in at ...See details»


eli-lilly-tops-q4-earnings-forecast-lifts-2023-outlook-on-trulicity-strength-image

Eli Lilly Tops Q4 Earnings Forecast, Lifts 2023 Outlook, On Trulicity Strength

Source from : TheStreet.com on MSN - 6 days ago

"Over the course of this critical year, we hope to launch as many as four new medicines for challenging diseases, while advancing our next generation of molecules currently in Phase 3." said CEO David ...See details»


Eli Lilly and Company (LLY) 41st Annual J.P. Morgan Healthcare Conference (Transcript)

Source from : Seeking Alpha - 29 days ago

I'm Chris Schott at J.P. Morgan, and it's my pleasure to be hosting this fireside chat with Eli Lilly ... So from Lilly, we have Anat Ashkenazi, the company's CFO, as well as Dan Skovronsky ...See details»


Should You Be Impressed By Eli Lilly and Company's (NYSE:LLY) ROE?

Source from : Yahoo - 1 month ago

By way of learning-by-doing, we'll look at ROE to gain a better understanding of Eli Lilly and Company (NYSE:LLY). Return on equity or ROE is a key measure used to assess how efficiently a company ...See details»


Eli Lilly to expand Durham campus, add 100 jobs

Source from : The Business Journals - 15 days ago

Pharmaceutical giant Eli Lilly and Company (NYSE: LLY) is expanding its Durham campus with an additional investment of $450 million that will create 100 jobs. The Indianapolis-based company says ...See details»


Eli Lilly and Company (NYSE:LLY) is a favorite amongst institutional investors who own 84%

Source from : Yahoo! Sports - 1 month ago

To get a sense of who is truly in control of Eli Lilly and Company (NYSE:LLY), it is important to understand the ownership structure of the business. The group holding the most number of shares in ...See details»


FDA rejects Eli Lillyโ€™s proposed Alzheimerโ€™s treatment, says more data needed

Source from : MarketWatch - 20 days ago

The setback could delay a potential commercial introduction of the highly anticipated drug by at least several months, if the Food and Drug ...See details»